1. Show article details.

    The Rise of the 'Stichting,' an Obscure Takeover Defense

    DJ Business News – 12:30 PM ET 04/22/2015

    LONDON--A centuries-old Dutch legal structure that has become a popular self-defense tool for companies and wealthy individuals could play a leading role in a takeover battle now shaping up. Israel's Teva Pharmaceutical Industries Ltd. (TEVA) said Tuesday it is bidding $40 billion for Mylan NV (MYL), a drug company with headquarters in Canonsburg, Pa., but incorporated in the Netherlands. In early April, moving preemptively to thwart such an offer, a Dutch law firm submitted paperwork on...

  2. Show article details.

    Abbott says its payoff from Mylan deal surged

    Reuters – 12:09 PM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

  3. Show article details.

    Abbott says payoff from Mylan deal surges, as Mylan shares leap

    Reuters – 10:53 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

  4. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit

    DJ Business News – 9:55 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  5. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit -- Update

    DJ Business News – 9:31 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  6. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit

    DJ Business News – 9:22 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  7. Show article details.

    Abbott profit beats expectations, sales of branded generics jump

    Reuters – 9:09 AM ET 04/22/2015

    Abbott Laboratories (ABT) reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. Sales in the company's division that sells branded generic drugs in emerging markets, jumped 31.8 percent in the first quarter even after including the impact of the strong dollar.

  8. Show article details.

    Abbott Labs profit from continuing operations more than doubles

    Reuters – 8:05 AM ET 04/22/2015

    Abbott Laboratories' (ABT) net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.

  9. Show article details.

    Abbott Reports First-Quarter 2015 Results

    PR Newswire – 7:45 AM ET 04/22/2015

    ABBOTT PARK, Ill., April 22, 2015 Abbott today announced financial results for the first quarter ended March 31, 2015. "We're off to a good start this year, with particularly strong performance in our branded generics, international nutrition and global diagnostics businesses," said Miles D. White, chairman and chief executive officer, Abbott.

  10. Show article details.

    Mylan Is Too Big a Pill for Teva

    MarketWatch – 9:54 PM ET 04/21/2015

    Teva Pharmaceutical Industries (TEVA)' $40 billion offer for Mylan has much to recommend it. That doesn't mean it will happen at an acceptable price. For Teva, the logic for the cash-and-stock bid is straightforward.

  11. Show article details.

    What to Watch in the Day Ahead - Wednesday, April 22

    Reuters – 2:55 PM ET 04/21/2015

    Dow component Boeing Co (BA) is expected to report a rise in first-quarter profit, helped by increased deliveries. McDonald's Corp's (MCD) new CEO, Steve Easterbrook, has a lot on his plate. Facebook Inc (FB) is expected to post a first-quarter profit above the average analyst estimate, according to Thomson Reuters StarMine data.

  12. Show article details.

    New Blood Glucose Meter Provides People with Diabetes an Accurate, Affordable Solution for Glucose Testing-Without Insurance Copays

    PR Newswire – 9:00 AM ET 04/15/2015

    ABBOTT PARK, Ill., April 15, 2015 The cost of insurance premiums and employee medical claims continues to rise in the United States, which is especially challenging for people living with chronic conditions such as diabetes.

  13. Show article details.

    Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide

    PR Newswire – 9:00 AM ET 04/14/2015

    ABBOTT PARK, Ill., April 14, 2015 Today, Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide.

  14. Show article details.

    Boston Athletic Association And Abbott Announce Multiple-Year Sponsorship Of The Boston Marathon

    PR Newswire – 10:00 AM ET 04/13/2015

    BOSTON, April 13, 2015The Boston Athletic Association today proudly announced the beginning of a robust sponsorship agreement with global healthcare company Abbott to become an Official Sponsor of the Boston Marathon.

  15. Show article details.

    Mylan Bids $205/Share for Generic Drug Maker Perrigo--3rd Update

    DJ Business News – 12:25 PM ET 04/08/2015

    Mylan NV (MYL) has proposed acquiring Perrigo Co. (PRGO) in a cash-and-stock transaction that would value the maker of generic drugs at $205 a share. The proposal is worth about $30 billion based on Perrigo's (PRGO) share count of 147 million at March 30. The per-share offer of $205 in cash and stock is a 25% premium to Perrigo's (PRGO) close on April 3, the last trading day before Mylan's proposal. Shares of Perrigo (PRGO), a maker of over-the-counter health-care products, jumped 25% in midday trading to $205.66.

  16. Show article details.

    Mylan's bid for Perrigo leading to a $700 million payday for Abbott Labs

    MarketWatch – 12:18 PM ET 04/08/2015

    Investors in Perrigo Co. PLC (PRGO) aren't the only ones doing cartwheels after Mylan N.V.' s buyout proposal. Abbott Laboratories (ABT) owns 75 million, or 15.4%, of Mylan's shares, which makes Abbott the largest shareholder in its fellow drug maker. With Mylan's stock up $9.40, or 16%, at an all-time high in midday trade, Abbott is making $705 million on its investment on the day.

  17. Show article details.

    First-of-its-Kind Diabetes Technology Revolutionizes How Glucose Data is Collected and Analyzed for People in India

    PR Newswire – 9:00 AM ET 04/02/2015

    ABBOTT PARK, Ill., April 2, 2015 India has the third highest population of obesity, trailing only the United States and China. To provide tools to better manage diabetes, Abbott  has launched the FreeStyle® Libre Pro Flash Glucose Monitoring System in India—a transformative new glucose monitoring tool that fundamentally changes how doctors treat people with diabetes.

  18. Show article details.

    Abbott Hosts Conference Call for First-Quarter Earnings

    PR Newswire – 9:00 AM ET 04/01/2015

    ABBOTT PARK, Ill., April 1, 2015 Abbott will announce its first-quarter 2015 financial results on Wednesday, April 22, 2015, before the market opens.

  19. Show article details.

    Belgium's Biocartis plans IPO as European biotech interest grows

    Reuters – 4:44 AM ET 04/01/2015

    * IPO could raise 70-100 mln euros. * Rising biotech interest among European investors. * Follows flood of IPOs in the United States. By Philip Blenkinsop. Belgian molecular diagnosis company Biocartis Group is planning a listing on Euronext Brussels to fund expansion, it said on Wednesday, seeking to take advantage of growing European interest in the sector.

  20. Show article details.

    Blackstone shares slip after $1.2 billion hotel deal

    MarketWatch – 5:54 PM ET 03/30/2015

    By Wallace Witkowski and Sue Chang, MarketWatch. Amgen (AMGN) shares decline as similar rival drug moves ahead. SAN FRANCISCO-- Blackstone Group LP (BX) shares slipped in the extended session Monday after the private capital manager said it bought three hotels for $1.2 billion.

Page:

Today's and Upcoming Events

  • Jul
    15

    ABT to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Apr
    24

    Shareholders Meeting

  • Apr
    22

    ABT Earnings Conference Call at 9:00 AM Listen

  • Apr
    13

    ABT ex-Dividend for $0.24 on 4/13/2015

    • Announce Date: 2/20/2015
    • Record Date: 4/15/2015
    • Pay Date: 5/15/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.